EGFR and non-small cell lung carcinoma: The abnormal activation of the c-Met pathway in NSCLC mainly involves Met14 exon skipping mutations, Met fusion and overexpression, and MET amplification, which is also a resistance mechanism in EGFR-mutant NSCLC resistant to EGFR TKIs [259].